Framing and legitimating EU legal regulation of human gene-editing technologies: key facets and functions of an imaginary.

IF 2.4 2区哲学 Q1 ETHICS Journal of Law and the Biosciences Pub Date : 2021-08-16 eCollection Date: 2021-07-01 DOI:10.1093/jlb/lsaa080

Aurélie Mahalatchimy, Pin Lean Lau, Phoebe Li, Mark L Flear

{"title":"Framing and legitimating EU legal regulation of human gene-editing technologies: key facets and functions of an imaginary.","authors":"Aurélie Mahalatchimy, Pin Lean Lau, Phoebe Li, Mark L Flear","doi":"10.1093/jlb/lsaa080","DOIUrl":null,"url":null,"abstract":"<p><p>Gene-editing technologies, ie those able to make changes in the DNA of an organism, are the object of global competition and a regulatory race between countries and regions. There is an attempt to craft legal frameworks protective enough for users, but flexible enough for developers of gene-editing technologies. This article examines the imaginary built into the framing of EU-level legal regulation of human gene-editing technologies and identifies its three key related facets: the tension around naturalness; safeguarding morality and ethics; and the pursuit of medical objectives for the protection of human health. Concerns around the use of gene-editing technologies in relation to eugenics and human enhancement have produced a multifaceted imaginary. We argue that this imaginary not only places a limit on EU-level regulation, despite a strong EU competence in respect of the internal market, but also seeks to ensure its legitimation.</p>","PeriodicalId":56266,"journal":{"name":"Journal of Law and the Biosciences","volume":"8 2","pages":"lsaa080"},"PeriodicalIF":2.4000,"publicationDate":"2021-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/52/lsaa080.PMC8366714.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Law and the Biosciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jlb/lsaa080","RegionNum":2,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/7/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"ETHICS","Score":null,"Total":0}

引用次数: 5

Abstract

Gene-editing technologies, ie those able to make changes in the DNA of an organism, are the object of global competition and a regulatory race between countries and regions. There is an attempt to craft legal frameworks protective enough for users, but flexible enough for developers of gene-editing technologies. This article examines the imaginary built into the framing of EU-level legal regulation of human gene-editing technologies and identifies its three key related facets: the tension around naturalness; safeguarding morality and ethics; and the pursuit of medical objectives for the protection of human health. Concerns around the use of gene-editing technologies in relation to eugenics and human enhancement have produced a multifaceted imaginary. We argue that this imaginary not only places a limit on EU-level regulation, despite a strong EU competence in respect of the internal market, but also seeks to ensure its legitimation.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

构建和合法化欧盟人类基因编辑技术的法律法规:一个虚构的关键方面和功能。

基因编辑技术，即那些能够改变生物体DNA的技术，是全球竞争的对象，也是国家和地区之间监管竞赛的对象。有一种尝试是制定对用户足够保护，但对基因编辑技术开发者足够灵活的法律框架。本文考察了欧盟层面人类基因编辑技术法律监管框架中的想象，并确定了其三个关键相关方面:围绕自然性的紧张关系;维护道德伦理;而医学追求的目标为保护人类健康。对基因编辑技术在优生学和人类增强方面的使用的担忧产生了多方面的想象。我们认为，这一设想不仅限制了欧盟层面的监管，尽管欧盟在内部市场方面具有强大的能力，而且还试图确保其合法性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Law and the Biosciences Medicine-Medicine (miscellaneous)

CiteScore

7.40

自引率

5.90%

发文量

审稿时长

13 weeks

期刊介绍： The Journal of Law and the Biosciences (JLB) is the first fully Open Access peer-reviewed legal journal focused on the advances at the intersection of law and the biosciences. A co-venture between Duke University, Harvard University Law School, and Stanford University, and published by Oxford University Press, this open access, online, and interdisciplinary academic journal publishes cutting-edge scholarship in this important new field. The Journal contains original and response articles, essays, and commentaries on a wide range of topics, including bioethics, neuroethics, genetics, reproductive technologies, stem cells, enhancement, patent law, and food and drug regulation. JLB is published as one volume with three issues per year with new articles posted online on an ongoing basis.